Victory Capital Management Inc Orchard Therapeutics PLC Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$2.24 - $4.29 $173,008 - $331,342	-77,236 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$4.39 - $7.23 $16,598 - $27,336	-3,781 Reduced 4.67%	77,236 $339,000
Q1 2021 May 04, 2021	SELL	$4.39 - $9.08 $18,073 - $37,382	-4,117 Reduced 4.84%	81,017 $588,000
Q4 2020 Feb 01, 2021	SELL	$3.86 - $5.07 $23,086 - $30,323	-5,981 Reduced 6.56%	85,134 $368,000
Q3 2020 Nov 09, 2020	SELL	$4.11 - $6.45 $156,673 - $245,874	-38,120 Reduced 29.5%	91,115 $374,000
Q1 2020 May 04, 2020	SELL	$5.65 - $15.71 $40,273 - $111,980	-7,128 Reduced 5.23%	129,235 $973,000
Q4 2019 Feb 06, 2020	BUY	$10.15 - $15.58 $72,349 - $111,054	7,128 Added 5.52%	136,363 $1.88 Million
Q4 2019 Feb 04, 2020	SELL	$10.15 - $15.58 $72,349 - $111,054	-7,128 Reduced 5.23%	129,235 $1.61 Million
Q3 2019 Nov 12, 2019	BUY	$11.88 - $16.72 $1.54 Million - $2.17 Million	129,643 Added 1929.21%	136,363 $1.62 Million
Q4 2018 Feb 05, 2019	BUY	$12.4 - $18.7 $83,328 - $125,664	6,720 New	6,720 $106,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.